# Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

Source: https://onco.cc/trials/nct06750185/  
OnCo record `nct06750185` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of BNT317 DL1 in advanced solid tumours, run by BioNTech SE, now recruiting.

## Summary

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06750185 by BioNTech SE, with 248 participants planned, started 2025-01-13 and due to reach its primary completion in 2031-04. Interventions recorded: BNT317 DL1, BNT317 DL2, BNT317 DL3, BNT317 DL4, BNT317 DL5 and BNT317 DL6.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06750185
- Phase: 1/2
- Setting: A Phase I/II, First-in-human, Open-label Trial of the Safety, Efficacy, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Participants With Advanced Solid Tumors
- Sponsor: BioNTech SE
- Enrolled: 248

## Sources

- ClinicalTrials.gov NCT06750185: https://clinicaltrials.gov/study/NCT06750185

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [BioNTech](https://onco.cc/companies/biontech/)

---
JSON: https://onco.cc/api/v1/entities/nct06750185.json